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Abstract
RATIONALE AND OBJECTIVES: This article describes issues and methods that are specific to the measurement of
change in tumor volume as measured from computed tomographic (CT) images and how these would relate to the
establishment of CT tumor volumetrics as a biomarker of patient response to therapy. The primary focus is on the
measurement of lung tumors, but the approach should be generalizable to other anatomic regions. MATERIALS AND
METHODS: The first issues addressed are the various sources of bias and variance in the measurement of tumor
volumes, which are discussed in the context of measurement variation and its impact on the early detection of response
to therapy. RESULTS AND RESOURCES: Research that seeks to identify the magnitude of some of these sources of error
is ongoing, and several of these efforts are described herein. In addition, several resources for these investigations are
being made available through the National Institutes of Health–funded Reference Image Database to Evaluate Response
to therapy in cancer project, and these are described as well. Other measures derived from CT image data that might
be predictive of patient response are described briefly, as well as the additional issues that each of these metrics
may encounter in real-life applications. CONCLUSIONS: The article concludes with a brief discussion of moving from
the assessment of measurement variation to the steps necessary to establish the efficacy of a metric as a biomarker
for response.
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Introduction
Lung cancer is the most common cause of cancer death in both men
and women in the United States and has one of the lowest 5-year
survival rates of all cancers (approximately 15%) [1]. Despite the
many advances in imaging, genomics, and many other fields, this
survival rate has not changed significantly in more than 20 years.
While novel therapeutic agents are being introduced and evaluated
for effectiveness [2], therapeutic response assessment methods have
also not changed, despite significant advances in imaging technology.
Advances in computed tomography (CT) technology during the
past 10 years have included increasing the number of detector rows
(from typical single-detector row spiral systems in 1998 to the 64 to
320 detector row systems of 2009), decreased rotation times (down
to <0.3 seconds for a full rotation), helical scanning and recon-
struction techniques, and sophisticated radiation dose reduction
methods, all of which have led, along with other developments, to
exquisitely detailed descriptions of anatomy. The current multidetec-
tor row CT (MDCT) systems permit the acquisition of low-dose,
thin-slice (<1.5 mm) image data sets of a patient’s entire thorax in
a single breath hold (typically now between 5 and 10 seconds). These
very high resolution image data sets can also be used with advanced
three-dimensional techniques (volume-rendering, maximum-intensity
projection, surface-shaded display, etc) to visualize lung anatomy and
pathology with unprecedented detail, using relatively noninvasive tech-
niques. Therefore, MDCT has been used in the imaging of lung can-
cer, in studies investigating the early detection (e.g., screening, such as
[3–6]), diagnosis (e.g., using temporal scans to detect differences over
time such as [7,8]), and for the assessment of treatment response (see
the review by Gavrielides et al. [9]).
Currently, the best hope for the treatment of lung cancer cure is
surgical resection of a small peripheral lung nodule, which is possible
in approximately 15% of patients presenting with early-stage disease
(the other patients present with later-stage disease or are not surgical
candidates owing to comorbidities). Those patients not able to re-
ceive surgery are often treated with chemotherapy, with or without
associated external beam radiotherapy. Treatment protocols vary
across the country and may include group protocol studies and clin-
ical trials. New biologic response modifiers for lung cancer therapy
have recently received increased interest. These generally less-toxic
agents are designed to affect the tumor blood supply or other critical
pathways in cancer cell growth, differentiation, or metastatic processes.
The end point of such therapies may not be lung cancer “disappear-
ance” but rather tumor growth cessation.
Despite advances both in CT technology and our understanding
of lung cancer cellular and molecular mechanisms, the current standard
method to measure tumor response to therapy using CT remains the
Response Evaluation Criteria in Solid Tumors (RECIST), which is
based on unidimensional, linear measurements of tumor diameter
[10,11]. Because it is based on a series of linear measurements, RECIST
offers a simple approach that requires minimal effort. The RECIST
guidelines, however, presume that tumors are spherical and change
in a uniform manner. Significant variability in the RECIST mea-
sure ments exists across different observers [12], and published work
generally focuses on the surrogate of “best overall response,” with only
a few methods addressing other imaging end points such as “time to
progression” and “disease-free survival.” As a therapy response measure-
ment procedure, RECISTmaps linear data into an established set of
four discrete categories: complete response, partial response, stable dis-
ease, and progressive disease. These categorical bins, however, are quite
coarse, with most trial analyses critically pivoting on partial response
(defined by a 30% linear sum reduction) and progressive disease (de-
fined by a 20% increase in tumor dimension).
Because it uses only unidimensional linear measurements in its
assessment, the RECIST criteria does not fully use the much higher-
resolution data sets offered by CTor the advanced image segmentation
and visualization methods that can be used on these data sets and that
are, in fact, available on many commercial workstations. This limits the
ability to accurately reflect size changes that occur in the many lesions
that are not spherical in nature and may ultimately limit the ability to
identify early changes in patients undergoing treatment through such
an inherently flawed metric. The advances in CT technology described
above had led to the development of three-dimensional methods to
measure the volume of lung lesions, with the aim of developing more
accurate and consistent measurements, even for nonspherical lesions, to
ultimately better assess response over a shorter time interval.
This article investigates some of the issues in the use of high-
resolution CT data sets for measuring tumor volumes, specifically
in the problem of assessing the response to therapy involving tumors
in the lung. Potential sources of both bias and variance are identified
and discussed. Some investigations that are currently underway as part
of the NCI funded Reference Image Database to Evaluate Response to
therapy in cancer (RIDER) project [13] are described, as well as their
contribution to the overall investigations into understanding bias and
variance in this context. Finally, the relationship between measuring
bias and variance and the establishment of CT tumor volumetrics as
a biomarker are discussed.
This work was carried out as part of the RIDER project, and the
intent was to develop a consensus approach to the benchmarking of
software tools for the assessment of tumor response to therapy and to
provide a publicly available database of images and associated meta-
data. The RIDER project evolved from the Lung Image Database
Consortium (LIDC) project, which was funded by the National
Cancer Institute to create a publicly available database of annotated
thoracic CT scans as a reference standard for the development, train-
ing, and evaluation of computer-aided diagnostic methods for lung
cancer detection and diagnosis [14–20]. The RIDER project is cur-
rently generating a database of temporally sequential CT, magnetic reso-
nance imaging, and positron emission tomography scans of subjects
with cancer, collected longitudinally during the course of nonsurgical
cancer therapy. The database will also include phantom images of syn-
thetic tumors and short-interval patient scans for the evaluation of
the variance and bias inherent to change analysis software tools. The
RIDER project was initiated in 2004 as a collaboration between the
NCI’s Cancer Imaging Program, the NCI’s Center for Bioinformatics,
the National Institute of Biomedical Imaging and Bioengineering
(NIBIB), and the Prevent Cancer Foundation (formerly the Cancer
Research and Prevention Foundation), with information technology
support from the Radiological Society of North America. The RIDER
project is composed of academic researchers, program staff at NCI, and
members of the Cancer Biomedical Informatics Grid, National Institute
of Biomedical Imaging and Bioengineering, the Food andDrug Admin-
istration, and the National Institute of Standards and Technology.
Materials and Methods
Measurement Issues Specific to CT Tumor Volumetrics
While CT images have been used as the basis for treatment re-
sponse assessment using the RECIST criteria, many questions must
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be answered before CT tumor volumetrics can provide an accurate
and precise estimate of a patient’s response to therapy. As with the
companion articles, these issues will first be addressed with regards
to measuring bias and variance, specifically with regard to tumor vol-
ume as estimated through CT. Whereas some of these problems are
somewhat straightforward to address, others are not.
Bias. Bias is typically assessed by comparing one set of measure-
ments of a given object with another set of measurements made using
some external truth standard. For example, the volume of an object
on CT can be measured using the image data (e.g., counting the
number of voxels that are identified as being part of the object after
the application of a three-dimensional segmentation method and
then multiplying the number of voxels by the physical size of each
voxel). This measured value can then be compared with the estimated
“true volume” of the object using some external standard such as a water
displacement method.
Although this can be relatively straightforward for clearly identi-
fied and measurable test objects or phantoms, this is not at all
straightforward for in vivo tissues. Specifically for tumors, as long
as they remain in vivo, there is no method to reliably establish the
“true volume” of the tumor with an external standard. Figure 1 shows
an example of a tumor contoured by three different readers in an effort
to obtain expert delineations of the “true” tumor boundary (as part of
the experimental work described in Meyer et al. [20]). It should be
noted that the readers were provided the same drawing instructions.
As that article demonstrated, there is significant variability between
readers in many different kinds of lesions. Even if the tumor is excised,
there may be some distortion of the tissue (from incomplete resection
or resection of additional tissue connected to the tumor, or even com-
pression of the tissue) or just simple alteration of its physiological en-
vironment (blood loss, etc) that then prevents an accurate estimation
of the volume of the tumor when it was in its in vivo state.
Therefore, bias is often addressed using some simulated tumors or
phantom objects. These objects (described in more detail below) are
meant to serve as approximations for actual tumors by providing
similar x-ray attenuation properties and shapes. They also provide
the significant advantage that they can be measured (repeatedly if
necessary) using an external truth standard (e.g., volume displace-
ment or other method).
Variance. Variance is typically assessed by using repeated measure-
ments under the same measurement conditions. As described else-
where [9], there are many potential sources of variance. In the specific
problem of lung lesion measurement using CT image data, sources of
variance are introduced at many different stages of the measurement.
Because CT is an ionizing x-ray–based modality, repeated CT exami-
nations of the same patient are not generally performed owing to dose
Figure 1. (A) Original image of complex lung nodule from CT. (B, C and D) White outline shows contour from three different readers. All
readers were given the same drawing instructions (based on experimental work described in Meyer et al. [20]).
218 CT Assessment of Response to Therapy McNitt-Gray et al. Translational Oncology Vol. 2, No. 4, 2009
considerations. However, one study of repeat examinations was per-
formed at the Memorial Sloan Kettering Cancer Center, which is de-
scribed below. Whereas image acquisition and reconstruction is one
source of variance, several other sources of variance (described later
on) may be assessed through repeated measurements that will include
the effect of the reader and of the measurement tools (e.g., algorithms)
being used, as well as possible “learning” interactions between readers
and cases. Therefore, variance may be investigated to some extent from
phantom studies, but certain sources of variance may also be addressed
by using patient image data sets.
Because one very important source of variance between different
studies can be the patient image database that is used for measure-
ments, one of the major contributions of the RIDER project is the
collection of reference image data sets that are publicly available and
therefore allow direct comparison of results from different measure-
ment approaches on the exact same data sets. The purpose of these
reference data sets is to allow investigations into the relative magni-
tudes of different sources of variance and to develop methods and
best practices that will reduce variance from these various sources.
Again, the ultimate goal is to improve the assessment of the response
to therapy in as universal a context as achievable in practice.
Potential sources of bias and variance in CT tumor volumetrics
within the lung. This section identifies and discusses some poten-
tial sources of bias and variance that are specific to the problem of
measuring tumor volumes within the lung using CT. These sources
of variability have been broken down into a few categories: 1) scanner-
related, 2) patient-related, 3) tumor-related, 4) measurement method–
related, and 5) interactions between sources of variance.
CT scanner–related factors. These describe factors that can
vary within and between CT scanners and that may introduce some
bias and variance into the measurement of lung volumes. In a multi-
center clinical trial, investigators rarely have any choice about what
scanner is to be used to image patients in the trial; similarly, in clin-
ical practice, repeat scans of patients are often acquired with different
scanners owing to scanner availability and scheduling limits. The
physical hardware–based differences between scanners can be a po-
tential source of bias and variance. Specifically, the manufacturer
and model of the CT scanner as well as the number of detector rows,
differences in detector material, the x-ray spectrum, and filtration
materials (e.g., bow tie filter composition), as well as different avail-
able options for image reconstruction may all affect the basic image
acquisition abilities and physical properties of the scanner. For exam-
ple, when a scanner with only four detector rows or less is used, it can
be difficult to obtain thin slices (≤1.5 mm) through the entire thorax
within a single breath hold, whereas this can be routinely performed
with a 64–detector row scanner.
In addition to the basic properties of the scanner itself are the dif-
ferences in imaging protocol, or how the scanner is actually being
used. This includes technical parameters settings such as kilovolt
peak (kV[p]), milliampere-second (mA s), beam collimation, and heli-
cal pitch (when helical scanning is performed). Note that similar nom-
inal settings on different scanners does not guarantee identical physical
properties of the reconstructed images. For example, using a setting of
120 kV(p) on MDCTs from different manufacturers may not result in
the same spectrum of x-ray beam energies to the patient, primarily be-
cause of differences in x-ray beam filtration, etc In addition to image
acquisition parameters, the reconstructed image parameters may also
play a significant role, such as reconstructed slice thickness (e.g., thin
slice or thicker slices), spacing or interval between reconstructed images
(e.g., creating overlap or not), reconstruction kernel (which has a sig-
nificant impact on noise and resolution properties) and pixel size/
reconstructed field of view. Any of these may have a significant impact
on the final image resolution (in the x-y plane, or z plane), noise, and
contrast resolution. Moreover, these parameters interact with other
sources of variability, such as nodule size, as will be described in the
remainder of this article.
The imaging protocol may also include fundamental decisions
about whether the acquisition is performed in a single helical pass
through the chest or as multiple overlapped passes over various por-
tions of the patient’s body. For example, one common imaging pro-
tocol is to scan through the entire chest down to the lung bases and
slightly into the abdomen, then have a slight delay (for iodinated
contrast to arrive in the abdominal organs), move superiorly slightly
and then scan from the top of the diaphragm through the abdomen,
thereby creating a region of scanning overlap. Another common im-
aging protocol is to eliminate that overlap region by performing the
first phase of the scan through the thorax, stopping at the top of the
diaphragm, having the contrast delay, and then scanning—without
moving back—from the top of the diaphragm down through the ab-
domen. One can also envision in the future that larger numbers of
detector rows or flat-panel CTs will allow for image acquisition in a
single-axial cone-beam CT acquisition.
The imaging protocol may also have some specific description of
the use of intravenous (IV) or oral contrast, whereas some studies
may be performed without contrast. In particular, when IV contrast
is used, images will be affected by the injection rate and volume of
contrast used (and whether that volume used is specified based on
patient weight or some other method), the type and concentration
of contrast used (there are a variety of concentrations commercially
available) as well as the delay used (how long after the injection the
scanning should be performed to allow the contrast to arrive at struc-
tures of interest) may all affect the characteristics and appearance of
the images before subsequent analysis.
Finally, the scanner’s calibration and maintenance can also be
placed under the scanner-related category. Some studies may require
that a quality assurance phantom be scanned at some interval (or
even alongside each patient). The study quality assurance process
may involve some physical measurements to determine the scanner’s
calibration to reference materials such as water and air. There may
also be an assessment of the Hounsfield unit (HU) scale’s consistency
both at different points in time and even across the field of view of
the reconstructed image, as well as of the scanner’s contrast scale
(how do CT numbers change with different reference materials).
The scanner’s maintenance schedule and software upgrades may affect
whether parts like the x-ray tube have been changed or whether a new
calibration, reconstruction, or correction algorithm is being used. Any
of these items may have some effect on the scanners’ intrinsic image
quality in properties such as noise or resolution inherent contrast and
may therefore affect the estimation of tumor volume.
Patient-, tumor-, and analysis-related factors. In addition to
factors related to the CT scanner itself, there are many factors that
relate to the patient and analysis method that may ultimately influ-
ence the measurement of tumor volumes. These are described in
more details in [21] that describes non–modality-dependent factors.
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Results and Resources
RIDER and RIDER-Related Investigations into Source of
Error for CT Volumetrics
As stated above, the purpose of the RIDER project is to provide
image data (and other relevant data if possible) to allow investigations
into sources of error and methods to reduce them. This section will
describe several data sources that are provided through RIDER and
describe how they may be used to understand bias and variance in
tumor volume measurements.
Patient Repeat CTs (“Coffee Break Experiment”) Performed at
Memorial Sloan Kettering Cancer Center
As part of a study evaluating variability in tumor measurements
from same-day repeat CT scans of patients with non–small cell lung
cancer [22], 32 patients were imaged twice on the same scanner at an
interval less than 15 minutes apart, with the patient getting off the
scanner bed between scans. This unique experiment represents repeat
scans under a presumed “no change” condition. The imaging was done
on one of two CT scanners (LightSpeed 16 or VCT; GE Medical Sys-
tems, Waukesha, WI), with 16 or 64 detector rows, respectively. The
LightSpeed 16 was used for 28 of the subjects, and 4 of them were
scanned on the VCT. Identical technical parameter settings were used
for both baseline and repeat scans. The following settings were used:
i. 120 kV(p)
ii. detector configuration of 16 × 1.25 mm (64 × 0.625 mm for
the VCT)
iii. pitch of 1.375:1 (0.984 for the VCT)
iv. rotation time of 0.5 second.
v. The standard-dose thoracic images were obtained without IV
contrast during a single breath hold.
vi. Thin-section images of 1.25 mm were reconstructed using
the lung convolution kernel.
vii. Patients were given the same breathing instructions for
both studies.
As with other RIDER data sets, the repeat scans data sets are being
made available to the public through the National Biomedical Imag-
ing Archive (NBIA) Web archive (http://ncia.nci.nih.gov/). It should
be noted that no annotations of the images have been provided (i.e.,
no reader markings or measurements).
Because these data sets were acquired during such a short time in-
terval, they represent a nearly ideal “no change” condition during this
period. However, the image data sets are not expected to be identical
because of issues described above (and in the Appendix of the com-
panion article by Meyer et al.), including differences in patient posi-
tioning, patient inspiration level, etc However, because these data sets
do represent the same lesions under identical parameter settings, they
should ideally translate into null bias and variance across repeat mea-
surements and can therefore be used in investigations about minimum
detectable change.
Unmarked CT Lung Studies at Different Time Intervals from
UT-MD Anderson Cancer Center
In this study, many cases of patients with known tumors in the
lungs (both primary and metastatic lesions are included) were sub-
mitted to NBIA under the RIDER collection. Each case had at least
two image data sets from different time points; many had three or
more time points. These cases were collected all from the same insti-
tution, as part of their clinical operation. Therefore, neither was there
a specific attempt either to collect the data prospectively nor was their
any specific attempt to standardize the imaging protocol beyond
what is already done as part of that site’s clinical operation. There-
fore, although scans were typically performed with the same acqui-
sition protocols on similar scanners for each exam, there is no
guarantee that this was the case because this was not one of the in-
clusion criteria (however, it should be noted that technical parameter
information is available through DICOM headers of these cases so
this could be evaluated by users of the database).
Whereas neither this site nor anyone else has provided annotations
of the complete tumor boundaries, as part of the original RIDER
project, two radiologists (C. Jaffe and R. Gottlieb) did provide RE-
CISTmeasurements on approximately 30 of the cases. These anno-
tations are available through NBIA as well.
CT Lung Nodule Phantom from FDA Center for Devices and
Radiological Health
As part of a parallel effort, colleagues at the FDA’s Center for
Devices and Radiological Health, Office of Science and Engineering
Laboratories, Division of Imaging and Applied Mathematics have
acquired and scanned an anthropomorphic phantom (Multipurpose
Chest Phantom; Kyoto Kagaku Co Ltd, Kyoto, Japan). In this study,
several synthetic nodules of known size, composition, and shape were
placed inside the anthropomorphic phantom with and without attach-
ment to simulated lung vasculature. This phantom has been scanned
multiple times under different combinations of dose (i.e., low and high
mA s), slice thickness (thin and thick slices), pitch, and reconstruction
filter (smooth and sharp kernels). This provides a series of scans through
this phantom with different combinations of technical parameter set-
tings and therefore different combinations of noise and spatial resolu-
tion. These data sets are being made available through the NBIAWeb
site to allow various segmentation and volume calculation software
techniques to be used to estimate the volume of each lesion. In addi-
tion, this phantom has also been scanned at several different institutions
and similar imaging protocols have been performed using scanners from
different manufacturers and different numbers of detector rows (8-, 16-,
and 64-slice scanners) to investigate the variability between scans ob-
tained on different platforms.
As described above, one of the main advantages of using phantoms
is the ability to investigate bias as a difference from some externally
assessed “truth” standard. Because there is no concern over radiation
exposure, the phantom can be scanned repeatedly under different ac-
quisition conditions, that is, with different technical parameter set-
tings for a given scanner or across various models. Analysis of this
data will help in determining the effects on both bias and variance
of volume measurements under different technical parameter set-
tings. In addition, because known simulated lesions having different
size, shape, and composition are used, analyses can be performed to
investigate the interactions between technical parameters and a nod-
ule’s size, shape, or composition, for example, as a way to assess their
relative and combined impact on the final estimation of volume.
As it now stands, the database includes CT scans of the anthropo-
morphic chest phantom containing a vasculature insert to which syn-
thetic nodules have been attached. Synthetic nodules in the set vary
in HU density values (−630 HU, −10 HU, and +100 HU), size (5, 8,
10, 20, and 40 mm), and shape (spherical, elliptical, lobulated, and
spiculated). Imaging protocols included variable exposure (20, 100,
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and 200 mA s), pitch (0.9 and 1.2), reconstruction kernel (detail and
medium), slice collimation (16 × 0.75 and 16 × 1.5 mm), and slice
thickness (0.8, 1.5, and 3.0 for the 16 × 0.75-mm collimation, and
2.0, 3.0, and 5.0 for the 16 × 1.5-mm collimation). Ten repeat scans
for each protocol were acquired using a 16-row multidetector CTscan-
ner (IDT Mx8000; Philips Medical Systems, Cleveland, OH). Scans
were also collected on a 64-row multidetector CT scanner (Sensation
64; Siemens Medical Solutions, Forcheim, Germany) for a subset of
the protocols described above. This database of CT scans is available
to the public through the NBIA, which is located at https://imaging.
nci.nih.gov/ncia/. Nonspherical nodular data sets will be released as
they become available.
All human subject studies were approved by the respective institu-
tional review board, and written informed consent was provided by
each subject.
Discussion
Mitigation Measures
Although it will take some time to complete the above data acqui-
sition and analyses to provide specific advice on bias and variance in
the CT tumor volumetrics problem, in the short term, some advice
may still be provided about mitigation measures that should reduce
the previously detailed sources of error. An overarching advice is to
keep as many potential sources of variance as possible exactly the
same across interval examinations, including the following:
1) Using the same device (same scanner)
2) Using the same technical parameter settings as previous ex-
aminations for any given patient (although some thought about
adjusting parameter settings owing to change in patient size,
such as weight gain or weight loss, may also be appropriate).
3) Using the same patient factors (positioning, breathing in-
structions, etc)
4) Performing analysis with the same software (e.g., manufacturer-
dependent)
5) Performing analysis with the same software settings (thresh-
old, etc) as previous examinations.
6) Performing analysis with the same software version if updates
were to add another source of variance (i.e., change in absolute
measurements) without improving the change analysis (e.g.,
when seeking relative rather than absolute changes)
7) On the basis of results from multiple studies [23–26], that sub-
centimeter nodules should be measured using thin-slice (≤1 mm)
imaging protocol.
Conclusions
The focus of this article has been the measurement of tumor volumes
in the lung using CT and the various sources of error one can en-
counter in that context. Different sources of error have been de-
scribed as well as investigations currently underway to address
many of these issues through an expanded understanding of bias
and variance. Data sets that either are or will soon be publicly avail-
able are described as well as their potential use in such investigations.
One limitation of this work is that, although it is very important
to understand sources of bias and variance and to be able to measure
their effects on the variable of interest (i.e., tumor volumes), this
work is not sufficient in itself to establish CT tumor volumetrics
as a biomarker. That is, these investigations may provide evidence
for reduced variability when using volume rather than when using
a linear measurement based metric such as RECIST. However, this
still does not indicate whether tumor volumetrics is a good predictor
of patient response to therapy. To establish that would require further
information not only on tumor volumes but also on the actual overall
response to therapy, which may be measured using patient outcome
data or metrics such as progression-free survival. Again, while the char-
acterization work introduced in this article is essential, it is clearly not
sufficient for the establishment of a biomarker. Further investigation
into alternate content-based metrics (e.g., density or even perfusion)
may be required, especially in light of new therapies that do not seek
to shrink tumors, but to cut off their blood supply and therefore to
render the tumor biologically inactive.
While the primary focus of this article is on activities surrounding
the RIDER CT tumor volumetrics effort, there are many other ana-
lyses and experiments that could be investigated with the collected
data sets. These include other metrics of change beyond just volume,
which could include changes in tumor density and composition.
Such analyses could readily be carried out with the data sets described
in this article. Other parameters, such as functional descriptions of
perfusion or permeability, would require data sets acquired under dif-
ferent image acquisition protocols that would involve dynamic imag-
ing of the lesions. Although these new data sets could further exploit
the RIDER framework, they would also require a careful analysis of
the sources of variance and covariates in a similar fashion as explored
herein with volumetric analysis of tumors on CT.
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